July 14, 2011 – Cambridge Heart Inc., a developer of non-invasive diagnostic tests for cardiac disease, announced that it has reached an agreement with its original equipment manufacturing (OEM) partner, Cardiac Science Corporation, to include Cambridge Heart’s proprietary microvolt T-wave alternans (MTWA) module on every new Q-Stress system sale beginning July 11, 2011. The company expects this initiative to significantly increase the placement of MTWA modules in coming quarters, which Cambridge Heart anticipates will provide the basis for future recurring revenue.
In order to maximize the commercial benefit of this initiative, Cambridge Heart and Cardiac Science have agreed to include the MTWA module in all new Q-Stress systems at no incremental cost through the end of 2011.
Sudden cardiac arrest (SCA) is the leading cause of death in the United States, accounting for an estimated 300,000 deaths each year – more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8 percent, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients who can benefit from annual MTWA testing. Microvolt T-wave alternans is a marker of SCA risk that is measured during a non-invasive treadmill test using Cambridge Heart’s proprietary technologies. The company’s MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy.
For more information: www.cambridgeheart.com
June 16, 2026 
